The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.a

Pneumonitis (interstitial lung disease/ILD)

Publications

Omotani S, Ishizaka T, Inoue M, Nishida K, Yasui Y, Hatsuda Y, Mukai J, Myotoku M

Drug-induced lung disease adverse effect with Ledipasvir Acetonate/Sofosbuvir.

Journal of pharmaceutical health care and sciences 2020;6;6 — 2020 — 6

Kawaoka T, Imamura M, Morio K, Nakamura Y, Tsuge M, Nelson Hayes C, Kawakami Y, Aikata H, Ochi H, Ishiyama K, Ohdan H, Chayama K

Three patients treated with sofosbuvir plus ledipasvir for recurrent hepatitis C after liver transplantation.

Clinical journal of gastroenterology 2017 Apr;10;179-184 — 2017 Apr — 179-184

Helmers RA, Byrne TJ, Wesselius LJ, Leslie KO

Serious Pulmonary Toxicity Secondary to Novel Hepatitis C Antiviral Therapy in a Liver Transplant Recipient.

Mayo Clinic proceedings 2015 Sep;90;1294-7 — 2015 Sep — 1294-7